Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propranolol + Etizolam is a fixed-dose combination therapy marketed by Brainwave Healthcare for the management of anxiety disorders, particularly situational anxiety and conditions characterized by physiological symptoms of autonomic arousal. Propranolol is a non-selective beta-adrenergic receptor antagonist that reduces peripheral symptoms such as tachycardia, tremors, and sweating by blocking the effects of epinephrine and norepinephrine on beta receptors. Etizolam is a thienodiazepine derivative that acts as a positive allosteric modulator at the benzodiazepine binding site of the GABA-A receptor, enhancing the inhibitory effects of GABA to provide central anxiolytic, sedative, and muscle relaxant properties. This combination is widely used in India to provide both central and peripheral relief from anxiety symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propranolol + etizolam.